Instil Bio, Inc. Common Stock (TIL) Stock Price

TILStock
$5.91−70.71%52W
Market Cap$40.08M
P/E—
PEG Ratio—
Div yield—
Beta1.92

TIL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-39.88%
Price vs S&P 500 (4W)-15.08%
VGM Score36.23

TIL Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.35-$0.63-80.00%(-$0.28)
Q1 2026-$0.59-$0.62-5.08%(-$0.03)
Q4 2025-$3.78-$0.97+74.34%(+$2.81)
Q3 2025-$3.04-$1.75+42.43%(+$1.29)
Q2 2025-$2.44-$2.88-18.03%(-$0.44)

TIL Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.00
4.00
4.00
4.00

Industry Peers — Biological Products(186)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
TILInstil Bio, Inc. Common Stock
——D————$5.91
AMGNAmgen IncDCA6.1x9.1%74.3%2.9%$432.49
GILDGilead Sciences IncCBA6.4x5.5%79.6%133.6%$156.19
MRNAModerna, Inc. Common StockFCA39.1x-27.6%36.4%—$218.01
ARGXargenx SE American Depositary SharesDAB6.6x165.2%89.8%—$819.14
RVMDRevolution Medicines, Inc. Common StockF—B3296.2x———$177.96
BIIBBiogen Inc. Common StockCDA3.4x0.3%74.0%-18.8%$232.65
BNTXBioNTech SE American Depositary ShareCCC7.6x-11.8%79.2%—$87.71
EXELExelixis IncCBA6.3x9.2%96.5%31.1%$62.23
HALOHalozyme Therapeutics, Inc.DBA8.3x41.1%82.4%22.9%$121.84
NBIXNeurocrine Biosciences IncCBB4.1x34.4%98.0%2.3%$135.71

About Instil Bio, Inc. Common Stock

Instil Bio is a clinical-stage biopharmaceutical company developing cell therapy treatments for cancer using tumor infiltrating lymphocytes (TILs). The company's proprietary CoStAR platform enables genetic engineering of TILs to enhance their recognition of tumor-associated antigens. Its lead candidate, ITIL-306, is in clinical development for multiple solid tumors including ovarian, uterine, non-small cell lung cancer, and renal cancer.